{"entity":{"id":"nct01975701","kind":"trial","name":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","aka":[],"tldr":"A phase 2 trial of Infigratinib in Glioma & glioblastoma, run by Novartis Pharmaceuticals, completed.","summary":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM is a phase 2 interventional study registered as NCT01975701 by Novartis Pharmaceuticals, with 26 participants recorded, started 2013-12-09 and reaching its primary completion in 2018-10-03. Interventions recorded: BGJ398. Conditions recorded: Recurrent Glioblastoma or Other Glioma Subtypes.\n\nLinked to the drug Infigratinib because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01975701","url":"https://clinicaltrials.gov/study/NCT01975701"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["infigratinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01975701","phase":"2","setting":"A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma","sponsor":"Novartis Pharmaceuticals","enrolled":26,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01975701/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/"}]}}